Safety and side effects of semaglutide and tirzepatide for managing obesity

This review suggests tirzepatide may have a more favorable side-effect profile than semaglutide for obesity management while offering renal and bone-related advantages.

This is a review of post-marketing safety and tolerability reports on semaglutide and tirzepatide, covering gastrointestinal, pancreatic, bone, kidney, and thyroid effects.

Because this is a review of reported post-marketing concerns rather than a direct comparative trial, the safety advantage for tirzepatide remains observational and subject to reporting bias.